



Atty. Docket No. A32362 (072396.0174)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Giannoukakis *et al.*
Serial No. : 09/320,767 Examiner : Angell, J.
Filed : May 27, 1999 Group Art Unit: 1635
For : GENE TRANSFER TO PANCREATIC CELLS FOR
PREVENTION OF ISLET DYSFUNCTION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

October 5, 2004

Date of Deposit

Rochelle K. Seide

Attorney Name

32,300

PTO Registration No.

Rochelle K. Seide
Signature

October 5, 2004

Date of Signature

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In supplement to the Information Disclosure Statement filed on December 17, 1999, and pursuant to the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants respectfully request that the publication relating to the above-mentioned application listed

10/08/2004 MAHMED1 00000018 09320767

03 FC:1806

180.00 OP

herein and on the accompanying PTO Form 1449 be considered by the Examiner and made of record in the U.S. Patent and Trademark Office.

The publication contained herein is identified as number 48 to distinguish it from the 47 publications previously disclosed in the above-identified application. The citation listed below is also listed in the accompanying PTO Form 1449.

48. Bertera S, Alexander AM, Crawford ML, Papworth G, Watkins SC, Robbins PD, Trucco M. Gene Combination Transfer to Block Autoimmune Damage in Transplanted Islets of Langerhans. *Experimental Diabetes Research* 2004;5:201-210.

The submission of this Supplemental Information Disclosure Statement does not represent that a search has been made or that no better art exists, and does not constitute an admission that any of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should this document be applied against the claims of the present application.

Applicants believe a fee of \$180.00 is required under 37 C.F.R. § 1.17(p) for submission of this Supplemental Information Disclosure Statement, and accordingly enclose a check for \$180.00. If any other fee is required in connection with this

communication or any overpayment has been made, please charge any deficiency or credit any overpayment to Deposit Account No. 02-4377. Two copies of this communication are enclosed.

Respectfully submitted,

BAKER BOTTS L.L.P.

A handwritten signature in black ink, reading "Rochelle K. Seide". The signature is written in a cursive style with a large, looping initial "R".

Rochelle K. Seide

Patent Office Reg. No. 32,300

Attorney for Applicants

(212) 408-2626

Enclosures

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A32362 (072396.0174)	Serial No. 09/320,767
	Applicant Giannoukakis <i>et al.</i>	
	Filing Date May 27, 1999	Group 1635
	Examiner Angell, J.	

U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appro.

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

48.	Bertera S, Alexander AM, Crawford ML, Papworth G, Watkins SC, Robbins PD, Trucco M. Gene Combination Transfer to Block Autoimmune Damage in Transplanted Islets of Langerhans. <i>Experimental Diabetes Research</i> 2004;5:201-210.
-----	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Examiner	Date Considered
----------	-----------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.